203
Views
45
CrossRef citations to date
0
Altmetric
Research Article

In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium

Pages 443-456 | Published online: 29 Sep 2008

References

  • ARSHADY, R., 1990, Microspheres and microcapsules, a survey of manufacturing techniques: part III: solvent evaporation. Polymer Engineering Science, 30, 915–924.
  • BOGDANSKY, S., 1990, Natural polymers as drug delivery systems. In Biodegradable Polymers As Drug Delivery Systems 1990, edited by M. ChasM and R. Langer (New York: Marcel Dekker, Inc.), pp. 231–259.
  • BozDAO, S., cALIS, S., KA$, S., SARGON, M. F., and HINCAL, A. A., 1998, In vitro evaluation of naproxen sodium loaded poly(D,L-lactide-co-glycolide) microspheres. Proceedings of the Bioencapsulation VII, USA.
  • BURGESS, D. J., and DAVIS, S. S., 1988, Potential use of albumin microspheres as a drug delivery system. II: in vivo deposition and release of steroids. international Journal of Pharmacy, 46, 69–76.
  • ALI$, S., BozDAO, S., KA$, S., and HINCAL, A. A., 1998, Formulation and characterization of albumin microspheres containing naproxen sodium. Proceedings of the 5th European Symposium on Controlled Drug Delivery, Noordwijk aan Zee, Netherlands, pp. 108–110.
  • CASTELLI, F., CONTI, B., FRESTA, M., CONTE, U., and Puqmsi, G., 1995, Stability evaluation of PDLLA microspheres loaded with anti-inflammatory drug. Proceedings of the 1st World Meeting APGIIAPV, Budapest, Hungary, pp. 407–408.
  • CWRCI, K., KA5, H. S., HINCAL, A. A., ERCAN, M. T., GtiVEN, 0., and RUACAN, S., 1996, In vitro and in vivo evaluation of PLAGA (50:50) microspheres containing 5-fluorouracil prepared by an evaporation method. International Journal of Pharmacy, 131, 73–82.
  • COHEN, S., YSHIOKA, T., LUCARELLI, M., HWAUC, L. H., and LANGER, R., 1991, Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microscopheres. Pharmaceutical Research, 8, 713–720.
  • EGBARIA, K., and FRIEDMAN, M., 1990, Sustained release albumin microspheres containing antibacterial drugs: effects of preparation conditions on kinetics of drug release. Journal of Controlled Release, 14,79–94.
  • ERCAN, M. T., ARAS, Y., UNLENEN, E., UNLU, UNSAL, I., and HAKELIK, Z., 1993,99mTc-Citrate versus 67Ga-Citrate for the scintigraphic visualization of inflammatory lesions. Nuclear Medicine Biology, 20, 881–887.
  • FLANDROY, P., GRANDFILS, C. H., DAENEN, B., SNAIS, F., DONDELINGER, R. F., JEROME, R., BASSLEER, R., and HEINEN, E., 1997, In vivo behavior of poly(D,L)-lactide microspheres designed for chemoembolization. Journal of Controlled Release, 44, 153–170.
  • GHADERI, R., and CARLFORS, J., 1997, Biological activity of lysozyme after entrapment in poly(D,L-lactide-co-glycolide)-microspheres. Pharmaceutical Research, 14, 1556–1562.
  • Guiziou, B., ARMSTRONG, D. J., ELLIOT, P. N. C., FORD, J. L., and ROSTRON, C., 1996, Investigation of in-vitro release charcteristics of NSAID-loaded polylactic acid microspheres. Journal of Microencapsulation, 13, 701–708.
  • GuPrA, P. K., and HUNG, C. T., 1989, Albumin microspheres I: physico-chemical characteristics. Journal of Microencapsulation, 6, 427–462.
  • HERMANN, J., and BODMEIER, R., 1998, Biodegradable somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods. European Journal of Pharmaceutics and Biopharmaceutics, 45, 75–82.
  • HUNNEYBALL, I. M., 1986, Intra-articular administration of drugs. Pharmacy International, May 7, 118–122.
  • JEYANT HI, R., THANOO, B. C., MEffrA, R. C., and DELucA, P. P., 1996, Effect of solvent removal technique on matrix characteristics of polylactide/glycolide microspheres for peptide delivery. Journal of Controlled Release, 38, 235–244.
  • KENLEY, R. A., LEE, M. 0 ., MAHONEY II, T. R., and SANDERS, L. M., 1987, Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro. Macromolecules, 20, 2398–2403.
  • MULLER, B. G., LEUENBERGER, H., and KISSEL, T., 1996, Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharmaceutical Research, 13, 32–37.
  • MUMPER, R. J., MILLS, B. A., RYO, Y. U., and JAY, M., 1992, Polymeric microspheres for radionuclide synovectomy containing neutron-actived Holmium-166. Journal of Nuclear Medcine, 33, 398–402.
  • NASIRIDEEN, S., KA5, H. S., PEK SOY, I., ERCAN, M. T., HAKELIK, Z., öNER, F., and H INCAL, A. A., 1998, Naproxen incorporated lipid emulsions III. anti-inflammatory effect in a rabbit model. S. T. P. Pharmaceutical Sciences, 8, 45–48.
  • P AVANET T 0, F., GENT A, I., GIUNCHEDI, P., CONT I, B., and CONTE, U., 1994, Spray-dried albumin microspheres for the intra-articular delivery of dexamethazone. Journal of Microencapsulation, 11, 445–454.
  • RATCLIFFE, J. H., HUNNEYBALL, I. M., SMTTH, A., WILSON, C. G., and DAVIS, S. S., 1984, Preparation and evaluation of biodegradable polymeric systems for intra-articular delivery of drugs. Journal of Pharmacy and Pharmacology, 36, 431–436.
  • RATCLIFFE, J. H., HUNNEYBALL, I. M., WILSON, C. G., S MIT H, A., and DAVIS, S. S., 1987, Albumin microspheres for intra-articular drug delivery: investigation of their retention in normal and arthiritic knee joints of rabbits. Journal of Pharmacy and Pharmacology, 39, 290–293.
  • RUBIN, R. H., FISCHMAN, A. J., NEEDLEMAN, M., WILKINSON, R., CALLAHAN, R. J., KHAW, B. A., HANSEN, W. P., KREMER, P. B., and ST RAUSS, H. W., 1989, Radiolabelled, nonspecific, polyclonal human immunoglobulin in the detection of focal inflammation by scintigraphy: comparison with Gallium-67 citrate technetium-99-m-labelled albumin. Journal of Nuclear Medicine, 30, 385–389.
  • S CHUGENS, C., LARUEL LE, N., NIFIANT, N., GRANDFILS, C., JEROME, R., and TEYSSIE, P., 1998, Effect of the emulsion stability on the morphology and porosity of semicrystalline poly-L-lactide microparticles prepared by w/o/w double emulsion-evaporation. Journal of Controlled Release, 32, 75–82.
  • S HAH, S. S., CHA, Y., and PITT, C. G., 1992, Poly(glycolic acid-co-DL-lactid acid): diffusion or degradation controlled drug delivery? Journal of Controlled Release, 18, 261–270.
  • SONG, C. X., LABHASETWAR, V., MURPHY, H., Qu, X., HUMPHREY, W. R., SHEBUSKI, R. J., and LEVY, R. J., 1997, Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. Journal of Controlled Release, 43, 197–212.
  • TOMLINSON, E., BURGER, J. J., SCHOOLDERWOERD, E. M. A., and McVrE, J. G., 1984, Human serum albumin microspheres for intra-arterial drug targeting of cytostatic compounds. In Microspheres and Drug Therapy, edited by S. S. Davis, L. Illum, J. G. McVie and E. Tomlinson (Elsevier Science Publishers), pp. 75–99.
  • TUNcAY, M., cALI5 S., KA5, H. S., ERCAN, M. T., PEK SOY, I., and HINCAL, A. A., 2000a, In vitro and in vivo evaluation of diclofenac sodium loaded albumin microspheres. Journal of Microencapsulation, 17, 145–155.
  • TUNcAY, M., cALI5, S., KA5, H. S., ERCAN, M. T., PEKSOY, I., and HINCAL, A. A., 2000b, Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro and in vivo evaluation. International Journal of Pharmacy, 195, 179–188.
  • TUNcAY, M., çAL IS S., KA5 S. ERTHRK, H., and HINCAL, A. A., 1998, Diclofenac sodium incorporated biodegradable microspheres: antfinflammatory activity in the knee joints of rabbits. Proceedings of the Conference on Challenges for Drug Delivery and Pharmaceutical Technology, Japan, p. 188.
  • TUNcAY, M., çALIS, S., KAS, S., and HINCAL, A. A., 1997, Preparation and in vitro evaluation of diclofenac sodium loaded biodegradable microspheres. Proceedings of the 4th International Symposium on Biomedical Science and Technology, Turkey, pp. 55–58.
  • VURAL, I., KA5, H. S., HINCAL, A. A., and CAVE, G., 1990, Cyclophosphamide loaded albumin microspheres II. release characteristics. Journal of Microencapsulation, 7, 511–516.
  • WATTS, P. J., DAVIES, M. C., and MELIA, C. D., 1990, Microencapsulation using emulsification/solvent evaporation: an overview of techniques and applications. Critical Reviews in Therapeutic Drug Carrier Systems, 7, 235–259.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.